期刊文献+

甘草泻心汤治疗索拉非尼化疗后手足皮肤反应 被引量:12

下载PDF
导出
摘要 索拉非尼(多吉美)是目前治疗肝癌常用的靶向药物,是多种激酶抑制剂,具有双重抗肿瘤作用:首先可以抑制原癌基因(RAS)/丝氨酸/苏氨酸蛋白激酶(RAF)/有丝分裂原激活蛋白激酶(MEK)/细胞外调节蛋白激酶(ERK)信号传导通路直接抑制肿瘤生长;其次通过抑制血管内皮细胞生长因子受体(VEGFR)和血小板衍生因子受体(PDGR)而阻断肿瘤新生血管的形成。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第5期1218-1219,共2页 Chinese Journal of Gerontology
基金 国家临床重点专科建设项目经费资助(ZJ1601ZL041)
  • 相关文献

参考文献6

  • 1王英迪,孙凯,姜宏宇.索拉非尼治疗晚期肾癌的现状[J].中国医药指南,2012,10(30):448-449. 被引量:4
  • 2陈东,赵鹏,陈伟,殷晓煜,肖伟锴,梁力建.索拉非尼治疗晚期原发性肝癌的单中心经验[J].中华普通外科学文献(电子版),2012,6(6):31-34. 被引量:7
  • 3Miyaki D,Aikata H,Kan H,et al.Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy〔J〕.J Gastroenterol Hepatol,2013;28(12):1834-41.
  • 4Liu YJ,Zhu GP,Guan XY.Comparison of the NCI-CTCAE version 4.0and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma〔J〕.Oral Oncol,2012;48(6):554-9.
  • 5Abdel-Rahman O,Abdel-Wahab M,Shaker M,et al.Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma〔J〕.Med Oncol,2013;30(3):655.
  • 6朱云,程旸,李爱民.原发性肝细胞癌对索拉非尼耐药机制的研究进展[J].中国药理学通报,2013,29(6):752-755. 被引量:11

二级参考文献23

  • 1Bell munt J,Montagut C,Albiol S,et al.Present strategies inthe treatment of metastatic renal cell carcinoma:an update onmolecular targeting agents[J].BJU Int,2007,99(2):274-280.
  • 2Ratain MJ,Eisen T,Stadler WM,et al.PhaseⅡPlacebo-controlledrandomized discontinuation trial of sorafenib in patients with metastaticrenal cell carcinoma[J].J Clin Oncol,2006,24(16):2505-2512.
  • 3Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advanced clear-cell renal-cell carcinoma[J].N Engl J Med,2007,356(2):125-134.
  • 4Amato RJ,Zhai J,Willis J,et a1.A phaseⅡtrial of intrapatientdose-escalated sorafenib in patients with metastatic renal cellcancer[J].Clin Genitourin,2012,10(3):153-158.
  • 5Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet oncol, 2009, 10( 1 ) : 25-34.
  • 6Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. NEJM, 2008, 359(4) : 378-390.
  • 7Shim JH, Park JW, Choi JI, et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clinic Oncol, 2009, 135(4) : 617-625.
  • 8Baek KK, Kim JH, Uhm JE, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology, 2011, 80(3-4) : 167-174.
  • 9Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. JNCI, 2008, 100 (10) : 698-711.
  • 10Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology, 2005, 42(5): 1208-1236.

共引文献18

同被引文献171

引证文献12

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部